Quest Diagnostics Inc (NYSE: DGX) has reported earnings for its third fiscal quarter (ending September 30) of $2.01 versus $1.99 for the same period a year ago. For the latest four quarters through September 30, E.P.S. were $7.52 versus $6.76 for the same period a year ago.
Recent Price Action
Quest Diagnostics Inc (NYSE: DGX) stock enjoyed a very large increase of 6.9% on 10/22/24. The shares closed at $157.47. Moreover, trading volume in this advance was exceptionally high at 293% of normal. Relative to the market the stock has been strong over the last nine months and has risen 5.7% during the last week.
Current PriceTarget Research Rating
DGX is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Quest Diagnostics has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Quest Diagnostics has a neutral Appreciation Score of 54 but a good Power Rating of 83, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment